Drug Trial Radar · NCT03439137
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Feb 14, 2018
Primary completion
Dec 12, 2018
Study completion Jul 16, 2019
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
Conditions
- Anemia; Hemodialysis Dependent Chronic Kidney Disease
Interventions
MT-6548Drug
Oral tablet
Darbepoetin alfaDrug
Intravenous administration
MT-6548-matching placeboDrug
Oral tablet
Darbepoetin alfa-matching placeboDrug
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Hb Level of Week 20 and Week 24Time frame: Up to Week 24
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Research site
Aichi, Japan
Research site
Chiba, Japan
Research site
Fukui, Japan
Research site
Fukuoka, Japan
Research site
Fukushima, Japan
Research site
Gunma, Japan
Research site
Hiroshima, Japan
Research site
Hokkaido, Japan
Research site
Hyōgo, Japan
Research site
Ibaraki, Japan
Research site
Kagawa, Japan
Research site
Kagoshima, Japan
Research site
Kanagawa, Japan
Research site
Kumamoto, Japan
Research site
Kyoto, Japan
Research site
Miyagi, Japan
Research site
Nagano, Japan
Research site
Nagasaki, Japan
Research site
Ōita, Japan
Research site
Okayama, Japan
Research site
Okinawa, Japan
Research site
Osaka, Japan
Research site
Saitama, Japan
Research site
Shiga, Japan
Research site
Shizuoka, Japan
Research site
Tokushma, Japan
Research site
Tokyo, Japan
Research site
Yamagata, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.